Developer docs
API playgroundTry for free, no card

Search company profiles

Helix BioPharma

Full company profile

uuid0005atm

Namestring
Helix BioPharma
Legal namestring
Helix BioPharma Corp.
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Helix BioPharma Corp. is a clinical-stage oncology company developing a proprietary pipeline of bio-conjugate drug candidates that target Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6), a cell-surface protein overexpressed in hard-to-treat solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. The portfolio comprises L-DOS47 (Tumor Defence Breaker), a first-in-class antibody-enzyme conjugate (AEC) that delivers an enzymatic payload to neutralize tumor-microenvironment acidity and convert immunologically "cold" tumors "hot" (Phase Ib completed, Phase II planned in combination with pembrolizumab); LEUMUNA, an oral immune checkpoint modulator targeting purine nucleoside phosphorylase for graft-versus-leukemia effect in post-transplant leukemia relapse (US FDA Orphan Drug Designation, patent through 2041); and GEMCEDA, a first-in-class oral prodrug of gemcitabine combined with cedazuridine achieving approximately 90% bioavailability versus 10% for conventional oral gemcitabine. Discovery-stage CEACAM6-targeting bi-specific antibody-drug conjugates (ADCs) and radionuclide drug conjugates (RDCs) extend the platform into gastrointestinal, gynecological, and other solid tumors.

The company is pre-revenue, with no commercial products, and funds operations through equity private placements and convertible debentures; cash stood at C$2,842,000 as of April 30, 2026, up from C$65,000 as of July 31, 2025. The lead product L-DOS47 generated a 75% overall response rate in its Phase Ib NSCLC study, and preclinical combination with pembrolizumab yielded 70% greater tumor volume reduction versus pembrolizumab alone. Distribution currently flows through clinical trial sites (including Poland via a wholly-owned subsidiary), with planned transition to pharmaceutical wholesalers and specialty pharmacies upon regulatory approval.

Helix BioPharma is publicly listed on the TSX (HBP), OTC PINK (HBPCD), and FWB Frankfurt (HBP0), is headquartered in Vancouver, BC (relocating from Toronto), and is preparing for a Nasdaq uplisting under the Multijurisdictional Disclosure System (MJDS) framework. Customers are healthcare providers and oncology treatment centers serving patients with hard-to-treat solid tumors and post-transplant leukemia relapse; pricing has not been disclosed as no product is commercialized. Composition-of-matter patent coverage extends through 2036 (L-DOS47), 2041 (LEUMUNA), and 2043 (GEMCEDA), with key leadership drawn from multinational pharma including Mundipharma, Bristol-Myers Squibb, and EMD Serono.

Short descriptiontext

Helix BioPharma Corp. is a clinical-stage, pre-revenue oncology company developing proprietary CEACAM6-targeting bio-conjugate drug candidates—L-DOS47, LEUMUNA, and GEMCEDA—for hard-to-treat solid tumors and post-transplant leukemia relapse, publicly listed on TSX (HBP) and preparing for a Nasdaq uplisting.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage oncology, antibody-enzyme conjugates, immuno-oncology therapeutics, tumor microenvironment modulation, biopharmaceutical drug development
Industry1 code
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pre-revenue / Clinical-stage development
TypeLicensing Royalties
Description

Helix BioPharma is a pre-revenue clinical-stage company. The company is focused on developing its pipeline of oncology drug candidates through clinical trials. Revenue generation is contingent on successful clinical development, regulatory approval, and commercialization of its pipeline products.

helixbiopharma.com
2Private placement financing
TypeLicensing Royalties
Description

The company raises capital through private placement equity and convertible debenture financings to fund ongoing R&D operations and clinical development programs.

helixbiopharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1L-DOS47
Description

First-in-class clinical-stage antibody-enzyme conjugate (AEC) that modifies the tumor microenvironment of solid tumors, taking the brakes off the immune system's anti-tumour defences. Also known as Tumour Defence Breaker™.

helixbiopharma.com
+2 more records
Core offering1 text field

Helix BioPharma is a clinical-stage oncology biopharmaceutical company developing a proprietary pipeline of bio-conjugate drug candidates targeting CEACAM6-overexpressing solid tumors. Its lead asset L-DOS47 is a first-in-class antibody-enzyme conjugate for non-small cell lung cancer; LEUMUNA is an oral immune checkpoint modulator for post-transplant leukemia relapse; and GEMCEDA is an oral gemcitabine prodrug enabling at-home chemotherapy administration.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 75% overall response rate in Phase Ib NSCLC study with L-DOS47 + chemotherapy (pemetrexed/carboplatin), including one near-complete remission in heavily pre-treated Stage IV patients
+2 more records
Product overview1 text field

Helix BioPharma is a clinical-stage oncology company with a proprietary platform of bio-conjugates targeting CEACAM6-expressing solid tumors. The company's portfolio consists of lead candidate L-DOS47 (Tumor Defence Breaker), a clinical-stage antibody-enzyme conjugate that normalizes tumor microenvironment acidity to enhance immunotherapy efficacy; LEUMUNA, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse; and GEMCEDA, a pre-IND oral gemcitabine prodrug enabling convenient at-home dosing. The company is also advancing discovery-stage bi-specific ADCs and radionuclide drug conjugates leveraging the same CEACAM6-targeting foundation.

Product and service3 records
1L-DOS47 (Tumour Defence Breaker)
CategoryOncology Biologics / Antibody-Enzyme Conjugate
Description

First-in-class clinical-stage antibody-enzyme conjugate (AEC) that targets CEACAM6-overexpressing solid tumors and delivers a urease payload to neutralize tumor microenvironment acidity, restoring immune cell infiltration and enhancing checkpoint inhibitor efficacy in NSCLC and other hard-to-treat solid tumors. Composition-of-matter patent coverage through 2036.

2LEUMUNA (ulodesine hemiglutarate)
CategoryOncology Small-Molecule Immune Modulator
Description

Oral immune checkpoint modulator that inhibits purine nucleoside phosphorylase (PNP) to activate the donor immune system and induce a graft-versus-leukemia (GvL) effect in patients experiencing leukemia relapse after allogeneic stem cell transplantation. Holds FDA Orphan Drug Designation and patent protection through 2041.

3GEMCEDA
CategoryOncology Oral Chemotherapy Prodrug
Description

First-in-class oral prodrug of gemcitabine combined with cedazuridine (a dehydrogenase inhibitor) that enables convenient at-home oral administration with approximately 90% bioavailability versus 10% for conventional oral gemcitabine, supporting metronomic dosing and combination with checkpoint inhibitors. Patent coverage through 2043.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-05-01
Description

Helix BioPharma licensed MS 001 (a development program based on the same PNP inhibition platform as LEUMUNA) to MetaShape Pharma for exploration in obesity and potentially neurodegenerative disease. MS 001 is being developed separately from Helix's LEUMUNA program which focuses on post-transplant leukemia relapse.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Bolt Biotherapeutics is a clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs) that, like Helix's L-DOS47, target the tumor microenvironment and aim to convert cold tumors hot when combined with checkpoint inhibitors. Both companies share a bio-conjugate platform modality with first-in-class mechanisms for solid tumors.

TypeDirect peer
Description

CytomX develops masked, protease-activated antibody conjugates (Probodies) for oncology, a bio-conjugate approach with similar novel mechanism-of-action flavor to Helix's antibody-enzyme conjugates targeting CEACAM6. Both are clinical-stage and target tumor selectivity / TME modulation as core differentiators.

TypeDirect peer
Description

Pyxis Oncology is a clinical-stage biopharmaceutical company developing antibody-drug conjugates including bi-specific ADCs against cancer targets in solid tumors, directly overlapping with Helix's discovery-stage CEACAM6 bi-specific ADC program. Both companies pursue next-generation ADC design to address hard-to-treat tumors.

TypeDirect peer
Description

Mersana Therapeutics is a clinical-stage oncology company developing novel ADCs with proprietary conjugation platforms (Dolasynthen, ImmunoLynx) targeting solid tumors, comparable to Helix's CEACAM6 bio-conjugate platform and ADC pipeline. Both companies compete for oncology partnership/licensing dollars.

TypeDirect peer
Description

Bicycle Therapeutics develops bicyclic peptide-based conjugates (Bicycles) for oncology including tumor-targeted toxins and T-cell engagers, representing an alternative novel bio-conjugate modality with similar first-in-class positioning to Helix's antibody-enzyme conjugates. Both pursue differentiated chemistries against validated oncology targets.

TypeDirect peer
Description

Tubulis is a clinical-stage ADC developer focused on novel conjugation chemistries (P5 conjugation technology) and stable linkers for solid tumor ADCs, making it a direct peer to Helix's bi-specific ADC discovery program. Both innovate at the conjugation and linker chemistry layer of antibody-drug conjugates.

TypeDirect peer
Description

Marker Therapeutics is a clinical-stage cell therapy company developing MultiTAA-specific T cells for post-transplant leukemia relapse, directly comparable to LEUMUNA's graft-versus-leukemia (GvL) induction approach in post-allo-SCT leukemia. Both target the same orphan indication with novel immunologic strategies.

TypeBroad incumbent
Description

ImmunoGen, recently acquired by AbbVie for approximately $10.1B, is a pioneer in ADC technology including FDA-approved Elahere. As an established incumbent with broader oncology pipeline and resources, it provides a benchmark for the kind of ADC-platform exit Helix could pursue.

TypeEmerging player
Description

Actinium Pharmaceuticals is a clinical-stage oncology company developing targeted radiopharmaceuticals (Iomab-B, Actimab) including for AML and conditioning before transplant, addressing similar hematology/transplant indications as LEUMUNA. Both target niche oncology indications where no approved standard exists.

TypeEmerging player
Description

PharmaCyte Biotech develops encapsulated cell therapies combining prodrug-activation with tumor-targeted delivery, conceptually similar to Helix's tumor-microenvironment-modulating approach (L-DOS47 raises TME pH; PharmaCyte activates chemotherapy in tumor). Both pursue novel localized oncology mechanisms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Helix BioPharma

Oncology Biopharmaceuticalshelixbiopharma.com

Helix BioPharma Corp. is a clinical-stage, pre-revenue oncology company developing proprietary CEACAM6-targeting bio-conjugate drug candidates—L-DOS47, LEUMUNA, and GEMCEDA—for hard-to-treat solid tumors and post-transplant leukemia relapse, publicly listed on TSX (HBP) and preparing for a Nasdaq uplisting.

What Helix BioPharma does

Helix BioPharma Corp. is a clinical-stage oncology company developing a proprietary pipeline of bio-conjugate drug candidates that target Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6), a cell-surface protein overexpressed in hard-to-treat solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. The portfolio comprises L-DOS47 (Tumor Defence Breaker), a first-in-class antibody-enzyme conjugate (AEC) that delivers an enzymatic payload to neutralize tumor-microenvironment acidity and convert immunologically "cold" tumors "hot" (Phase Ib completed, Phase II planned in combination with pembrolizumab); LEUMUNA, an oral immune checkpoint modulator targeting purine nucleoside phosphorylase for graft-versus-leukemia effect in post-transplant leukemia relapse (US FDA Orphan Drug Designation, patent through 2041); and GEMCEDA, a first-in-class oral prodrug of gemcitabine combined with cedazuridine achieving approximately 90% bioavailability versus 10% for conventional oral gemcitabine. Discovery-stage CEACAM6-targeting bi-specific antibody-drug conjugates (ADCs) and radionuclide drug conjugates (RDCs) extend the platform into gastrointestinal, gynecological, and other solid tumors.

The company is pre-revenue, with no commercial products, and funds operations through equity private placements and convertible debentures; cash stood at C$2,842,000 as of April 30, 2026, up from C$65,000 as of July 31, 2025. The lead product L-DOS47 generated a 75% overall response rate in its Phase Ib NSCLC study, and preclinical combination with pembrolizumab yielded 70% greater tumor volume reduction versus pembrolizumab alone. Distribution currently flows through clinical trial sites (including Poland via a wholly-owned subsidiary), with planned transition to pharmaceutical wholesalers and specialty pharmacies upon regulatory approval.

Helix BioPharma is publicly listed on the TSX (HBP), OTC PINK (HBPCD), and FWB Frankfurt (HBP0), is headquartered in Vancouver, BC (relocating from Toronto), and is preparing for a Nasdaq uplisting under the Multijurisdictional Disclosure System (MJDS) framework. Customers are healthcare providers and oncology treatment centers serving patients with hard-to-treat solid tumors and post-transplant leukemia relapse; pricing has not been disclosed as no product is commercialized. Composition-of-matter patent coverage extends through 2036 (L-DOS47), 2041 (LEUMUNA), and 2043 (GEMCEDA), with key leadership drawn from multinational pharma including Mundipharma, Bristol-Myers Squibb, and EMD Serono.

Helix BioPharma firmographics

Firmographics
Name
Helix BioPharma
Legal name
Helix BioPharma Corp.
Website
https://helixbiopharma.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
Helix BioPharma Corp. is a clinical-stage, pre-revenue oncology company developing proprietary CEACAM6-targeting bio-conjugate drug candidates—L-DOS47, LEUMUNA, and GEMCEDA—for hard-to-treat solid tumors and post-transplant leukemia relapse, publicly listed on TSX (HBP) and preparing for a Nasdaq uplisting.
Ownership category
akta.pro rank

Helix BioPharma industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Clinical-stage oncology
  • Antibody-enzyme conjugates
  • Immuno-oncology therapeutics
  • Tumor microenvironment modulation
  • Biopharmaceutical drug development

Where Helix BioPharma is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices3 records

Markets served

Helix BioPharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Pre-revenue / Clinical-stage development: Helix BioPharma is a pre-revenue clinical-stage company. The company is focused on developing its pipeline of oncology drug candidates through clinical trials. Revenue generation is contingent on successful clinical development, regulatory approval, and commercialization of its pipeline products.
  2. Private placement financing: The company raises capital through private placement equity and convertible debenture financings to fund ongoing R&D operations and clinical development programs.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Helix BioPharma product offering

Product offering

Core offering

Helix BioPharma is a clinical-stage oncology biopharmaceutical company developing a proprietary pipeline of bio-conjugate drug candidates targeting CEACAM6-overexpressing solid tumors. Its lead asset L-DOS47 is a first-in-class antibody-enzyme conjugate for non-small cell lung cancer; LEUMUNA is an oral immune checkpoint modulator for post-transplant leukemia relapse; and GEMCEDA is an oral gemcitabine prodrug enabling at-home chemotherapy administration.

Product overview

Helix BioPharma is a clinical-stage oncology company with a proprietary platform of bio-conjugates targeting CEACAM6-expressing solid tumors. The company's portfolio consists of lead candidate L-DOS47 (Tumor Defence Breaker), a clinical-stage antibody-enzyme conjugate that normalizes tumor microenvironment acidity to enhance immunotherapy efficacy; LEUMUNA, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse; and GEMCEDA, a pre-IND oral gemcitabine prodrug enabling convenient at-home dosing. The company is also advancing discovery-stage bi-specific ADCs and radionuclide drug conjugates leveraging the same CEACAM6-targeting foundation.

Differentiator

Problem solved

Functional benefit

Brands

  • L-DOS47: First-in-class clinical-stage antibody-enzyme conjugate (AEC) that modifies the tumor microenvironment of solid tumors, taking the brakes off the immune system's anti-tumour defences. Also known as Tumour Defence Breaker™.
  • LEUMUNA™
  • GEMCEDA™

Products and services

  • L-DOS47 (Tumour Defence Breaker) First-in-class clinical-stage antibody-enzyme conjugate (AEC) that targets CEACAM6-overexpressing solid tumors and delivers a urease payload to neutralize tumor microenvironment acidity, restoring immune cell infiltration and enhancing checkpoint inhibitor efficacy in NSCLC and other hard-to-treat solid tumors. Composition-of-matter patent coverage through 2036.
  • LEUMUNA (ulodesine hemiglutarate) Oral immune checkpoint modulator that inhibits purine nucleoside phosphorylase (PNP) to activate the donor immune system and induce a graft-versus-leukemia (GvL) effect in patients experiencing leukemia relapse after allogeneic stem cell transplantation. Holds FDA Orphan Drug Designation and patent protection through 2041.
  • GEMCEDA First-in-class oral prodrug of gemcitabine combined with cedazuridine (a dehydrogenase inhibitor) that enables convenient at-home oral administration with approximately 90% bioavailability versus 10% for conventional oral gemcitabine, supporting metronomic dosing and combination with checkpoint inhibitors. Patent coverage through 2043.

Quantifiable outcome

  • 75% overall response rate in Phase Ib NSCLC study with L-DOS47 + chemotherapy (pemetrexed/carboplatin), including one near-complete remission in heavily pre-treated Stage IV patients
  • +2 more outcomes

Companies that use Helix BioPharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Helix BioPharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Helix BioPharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MetaShape PharmaminorOEM/ Whitelabel/ Licensing Partner · 1 May 2026Helix BioPharma licensed MS 001 (a development program based on the same PNP inhibition platform as LEUMUNA) to MetaShape Pharma for exploration in obesity and potentially neurodegenerative disease. MS 001 is being developed separately from Helix's LEUMUNA program which focuses on post-transplant leukemia relapse.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Helix BioPharma competitors and assessment

Company assessment

Direct peers

  • Bolt Biotherapeutics: Bolt Biotherapeutics is a clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs) that, like Helix's L-DOS47, target the tumor microenvironment and aim to convert cold tumors hot when combined with checkpoint inhibitors. Both companies share a bio-conjugate platform modality with first-in-class mechanisms for solid tumors.
  • CytomX Therapeutics: CytomX develops masked, protease-activated antibody conjugates (Probodies) for oncology, a bio-conjugate approach with similar novel mechanism-of-action flavor to Helix's antibody-enzyme conjugates targeting CEACAM6. Both are clinical-stage and target tumor selectivity / TME modulation as core differentiators.
  • Pyxis Oncology: Pyxis Oncology is a clinical-stage biopharmaceutical company developing antibody-drug conjugates including bi-specific ADCs against cancer targets in solid tumors, directly overlapping with Helix's discovery-stage CEACAM6 bi-specific ADC program. Both companies pursue next-generation ADC design to address hard-to-treat tumors.
  • Mersana Therapeutics: Mersana Therapeutics is a clinical-stage oncology company developing novel ADCs with proprietary conjugation platforms (Dolasynthen, ImmunoLynx) targeting solid tumors, comparable to Helix's CEACAM6 bio-conjugate platform and ADC pipeline. Both companies compete for oncology partnership/licensing dollars.
  • Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide-based conjugates (Bicycles) for oncology including tumor-targeted toxins and T-cell engagers, representing an alternative novel bio-conjugate modality with similar first-in-class positioning to Helix's antibody-enzyme conjugates. Both pursue differentiated chemistries against validated oncology targets.
  • Tubulis: Tubulis is a clinical-stage ADC developer focused on novel conjugation chemistries (P5 conjugation technology) and stable linkers for solid tumor ADCs, making it a direct peer to Helix's bi-specific ADC discovery program. Both innovate at the conjugation and linker chemistry layer of antibody-drug conjugates.
  • Marker Therapeutics: Marker Therapeutics is a clinical-stage cell therapy company developing MultiTAA-specific T cells for post-transplant leukemia relapse, directly comparable to LEUMUNA's graft-versus-leukemia (GvL) induction approach in post-allo-SCT leukemia. Both target the same orphan indication with novel immunologic strategies.

Broad incumbents

  • ImmunoGen: ImmunoGen, recently acquired by AbbVie for approximately $10.1B, is a pioneer in ADC technology including FDA-approved Elahere. As an established incumbent with broader oncology pipeline and resources, it provides a benchmark for the kind of ADC-platform exit Helix could pursue.

Emerging players

  • Actinium Pharmaceuticals: Actinium Pharmaceuticals is a clinical-stage oncology company developing targeted radiopharmaceuticals (Iomab-B, Actimab) including for AML and conditioning before transplant, addressing similar hematology/transplant indications as LEUMUNA. Both target niche oncology indications where no approved standard exists.
  • PharmaCyte Biotech: PharmaCyte Biotech develops encapsulated cell therapies combining prodrug-activation with tumor-targeted delivery, conceptually similar to Helix's tumor-microenvironment-modulating approach (L-DOS47 raises TME pH; PharmaCyte activates chemotherapy in tumor). Both pursue novel localized oncology mechanisms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Helix BioPharma social profiles

Digital presence

Helix BioPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Helix BioPharma leadership team

Management profile

Number of profiles

Profiles12 records

Helix BioPharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Helix BioPharma funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Helix BioPharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helix BioPharma

What does Helix BioPharma do?

Helix BioPharma is a clinical-stage oncology biopharmaceutical company developing a proprietary pipeline of bio-conjugate drug candidates targeting CEACAM6-overexpressing solid tumors. Its lead asset L-DOS47 is a first-in-class antibody-enzyme conjugate for non-small cell lung cancer; LEUMUNA is an oral immune checkpoint modulator for post-transplant leukemia relapse; and GEMCEDA is an oral gemcitabine prodrug enabling at-home chemotherapy administration.

Is Helix BioPharma a public or private company?

Helix BioPharma is a public company. It is classified as public and is currently operating.

When was Helix BioPharma founded?

Helix BioPharma was founded in 2007. It employs 1 to 10 people.

Where is Helix BioPharma based?

Helix BioPharma is headquartered in Toronto, Canada, in the North America region.

How does Helix BioPharma make money?

Two revenue lines are on record. Pre-revenue / Clinical-stage development is the primary driver. The others are private placement financing.

Who are Helix BioPharma's main competitors?

Direct peers on record are Bolt Biotherapeutics, CytomX Therapeutics, Pyxis Oncology, Mersana Therapeutics, Bicycle Therapeutics, Tubulis and Marker Therapeutics. ImmunoGen is listed as a broad incumbent. Emerging players are Actinium Pharmaceuticals and PharmaCyte Biotech.

Does Helix BioPharma have an API?

No public API is recorded for Helix BioPharma.

What industry is Helix BioPharma in?

Helix BioPharma's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewHelix BioPharma Corp. Announces Fiscal 2026 Year-End ResultsHelix BioPharma reported a fiscal 2026 net loss of $3.354 million, down from $5.205 million in 2025, with R&D expenses falling 54% to $1.62 million. The company has a working capital deficiency of $4.181 million and plans bridge financing for its L-DOS47 study.TradingViewHelix BioPharma Corp. (HBP) Posts FY26 Net Loss $3.35M, Cuts R&D 54%Helix BioPharma reported a FY26 net loss of $3.35M, down from $5.21M in FY25, with R&D expenses cut 54% to $1.62M. Cash on hand was $804K, and the company said funds are insufficient for 12 months, seeking financing. A secured bridge and larger raise to start the planned L-DOS47 trial would be the next catalyst.Stock TitanHelix BioPharma Corp. Announces Fiscal 2026 Year-End ResultsHelix BioPharma reported a net loss and total comprehensive loss for fiscal 2026 ended July 31, 2026. The company also announced the appointment of Markus Loeffler as Chief Medical Officer and an extension of its LEUMUNA agreement with metaShape through 2028. It plans bridge financing to support its planned Phase Ib/II study of L-DOS47.TradingViewEarly Warning Press Release Regarding The Disposition Of Common Shares Of Helix Biopharma Corp. By Jerzy WilczewskiJerzy Wilczewski sold 800,000 Helix Biopharma common shares at C$1.30 each, raising C$1,040,000. The sale reduced his stake from 10.93% to 9.88% of issued shares. He holds convertible debentures maturing August 2, 2027, which will affect his ownership calculation.TradingViewHelix Biopharma Corp. (HBP) Holder Cuts Stake by 800K SharesJerzy Wilczewski sold 800,000 Helix Biopharma shares at C$1.30 each in a private sale, reducing his stake from 10.93% to 9.88%. He holds 1,260 convertible debentures maturing Aug. 2, 2027, and the sale generated C$1.04 million in proceeds.FinancialContent Business PageEarly Warning Press Release Regarding The Disposition Of Common Shares Of Helix Biopharma Corp. By Jerzy WilczewskiJerzy Wilczewski sold 800,000 Helix Biopharma common shares at C$1.30 each, raising C$1,040,000. The sale reduced his ownership from 10.93% to 9.88% of the company. He may adjust his stake in future market transactions.The future of tradingHelix BioPharma names Karen Krumeich board chair, adds three directorsHelix BioPharma appointed Karen Krumeich, Jamieson Bondarenko, Charmaine Lykins, and Dirk Brockstedt to its board, effective Sept. 28, 2026. Krumeich was named board chair and audit committee chair, while Bondarenko joined the reconstituted audit committee. Three directors resigned.The future of tradingHelix BioPharma Strengthens Biotech Leadership and Corporate Governance through planned Board ChangesHelix BioPharma announced appointments of Karen Krumeich, Jamieson Bondarenko, Charmaine Lykins, and Dirk Brockstedt to its board, effective September 28, 2026, with Krumeich as chair. The company also reconstituted its audit committee, leaving six directors, four independent. The changes aim to strengthen governance as the company advances its oncology pipeline.Markets DailyHelix BioPharma (TSE:HBP) Stock Crosses Above 50-Day Moving Average – What’s Next?Shares of Helix BioPharma Corp. crossed above its 50-day moving average during Friday trading, reaching a high of C$2.05. The company recently reported a loss of C$0.01 per share for the quarter ended in June and currently holds a market capitalization of C$150.46 million.YahooHelix Biopharma Corp. Announces Board Composition ChangesHelix BioPharma Corp. has announced changes to its Board of Directors, effective immediately, including the resignation of Mr. Janusz Grabski and the appointment of CEO Thomas Mehrling as a director. These changes are aimed at aligning the Board with Helix's governance and capital market requirements as it continues its clinical development. Helix bioPharma is focused on developing therapies for difficult-to-treat cancers, including candidates like L-DOS47 for non-small cell lung cancer.